Bowlin T L, Rosenberger A, Stemerick D, Edwards M L
Merrell Dow Research Institute, Cincinnati, Ohio 45215.
Cancer Res. 1990 Sep 1;50(17):5460-3.
The objective of the present investigation was to evaluate the immunomodulating properties of tetramethylenebisacetamide (N,N' 1-diacetylputrescine, DAP), a known inducer of cellular differentiation. We examined the effect of DAP administration in vivo on splenic and nonadherent peritoneal natural killer (NK) cell activity. A single i.p. injection of DAP (100 mg/kg) enhanced cytolytic activity directed against YAC-1 and MCA-38 tumor target cells 2- to 3-fold. Cytolytic activity peaked 3 days following DAP injection. DAP treatment increased the frequency of asialo-GM1-positive splenocytes to 15% compared with 5% for vehicle treated controls. Furthermore, cytolytic activity could be eliminated by treatment with anti-asialo-GM1 antibodies and complement. Lysis of NK-resistant P815 and EL4 tumor target cells was not observed in leukocytes from DAP-treated mice. DAP treatment of mice given injections i.p. of MCA-38 tumor cells increased survival time of the mice by 37%, curing 10% of the animals of the tumor. DAP treatment of mice given injections intrasplenically of MCA-38 tumor cells reduced both the number and the size of the hepatic metastases. The antitumor effect of DAP in vivo could be eliminated by pretreating mice with anti-asialo-GM1 antibodies or utilizing NK cell deficient beige (bg/bg) mice. These results indicate that the observed anti-tumor activity of DAP is mediated, at least in part, by NK cells.
本研究的目的是评估四亚甲基双乙酰胺(N,N'-1-二乙酰腐胺,DAP)的免疫调节特性,它是一种已知的细胞分化诱导剂。我们检测了DAP体内给药对脾脏和非黏附性腹膜自然杀伤(NK)细胞活性的影响。单次腹腔注射DAP(100mg/kg)可使针对YAC-1和MCA-38肿瘤靶细胞的细胞溶解活性增强2至3倍。细胞溶解活性在DAP注射后3天达到峰值。与载体处理的对照组的5%相比,DAP处理使去唾液酸GM1阳性脾细胞的频率增加到15%。此外,用抗去唾液酸GM1抗体和补体处理可消除细胞溶解活性。在DAP处理的小鼠的白细胞中未观察到对NK抗性P815和EL4肿瘤靶细胞的裂解。对腹腔注射MCA-38肿瘤细胞的小鼠进行DAP处理可使小鼠的存活时间延长37%,使10%的动物肿瘤治愈。对脾内注射MCA-38肿瘤细胞的小鼠进行DAP处理可减少肝转移灶的数量和大小。DAP在体内的抗肿瘤作用可通过用抗去唾液酸GM1抗体预处理小鼠或利用NK细胞缺陷的米色(bg/bg)小鼠来消除。这些结果表明,观察到的DAP的抗肿瘤活性至少部分是由NK细胞介导的。